| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J Belin, J L Houéto, T Constans, C Hommet, B de Toffol, K Mondo. [Geriatric particularities of Parkinson's disease: Clinical and therapeutic aspects]. Revue neurologique. vol 171. issue 12. 2016-09-19. PMID:26573332. |
although historically pd has been characterized by the presence of progressive dopaminergic neuronal loss of the substantia nigra, the disease process also involves neurotransmitters other that dopamine and regions of the nervous system outside the basal ganglia. |
2016-09-19 |
2023-08-13 |
human |
| Hugo González, Francisco Contreras, Rodrigo Pachec. Regulation of the Neurodegenerative Process Associated to Parkinson's Disease by CD4+ T-cells. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 10. issue 4. 2016-09-15. PMID:26018603. |
microglial cells play a central role in the outcome of neuroinflammation and consequent neurodegeneration of dopaminergic neurons in the substantia nigra. |
2016-09-15 |
2023-08-13 |
Not clear |
| Richard M Zweig, Elizabeth A Disbrow, Vijayakumar Javalka. Cognitive and Psychiatric Disturbances in Parkinsonian Syndromes. Neurologic clinics. vol 34. issue 1. 2016-09-15. PMID:26614001. |
parkinsonian syndromes share clinical signs including akinesia/bradykinesia and rigidity, which are consequences of pathology involving dopaminergic substantia nigra neurons. |
2016-09-15 |
2023-08-13 |
Not clear |
| Renato S Monteiro-Junior, Thais Cevada, Bruno R R Oliveira, Eduardo Lattari, Eduardo M M Portugal, Alessandro Carvalho, Andrea C Deslande. We need to move more: Neurobiological hypotheses of physical exercise as a treatment for Parkinson's disease. Medical hypotheses. vol 85. issue 5. 2016-09-09. PMID:26209418. |
the degeneration of dopaminergic neurons in the substantia nigra and chronic inflammation impair specific brain areas, which in turn result in lesser motor control, behavioral changes and cognitive decline. |
2016-09-09 |
2023-08-13 |
Not clear |
| Chi Wang Ip, Sandra K Beck, Jens Volkman. Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996). vol 122. issue 12. 2016-09-09. PMID:26290125. |
cell counts of tyrosine hydroxylase positive dopaminergic neurons of the substantia nigra in immune compromised mice were significantly reduced compared to wild-type mice. |
2016-09-09 |
2023-08-13 |
mouse |
| S DeVaughn, E M Müller-Oehring, B Markey, H M Brontë-Stewart, T Schult. Aging with HIV-1 Infection: Motor Functions, Cognition, and Attention--A Comparison with Parkinson's Disease. Neuropsychology review. vol 25. issue 4. 2016-09-09. PMID:26577508. |
although there are clear diagnostic differences in the primary pathology of both diseases, i.e., death of dopamine-generating cells in the substantia nigra in pd and neuroinflammation in hiv, neurotoxicity to dopaminergic terminals in the basal ganglia (bg) has been implied in the pathogenesis of hiv and neuroinflammation in the pathogenesis of pd. |
2016-09-09 |
2023-08-13 |
Not clear |
| Ioannis U Isaias, Paula Trujillo, Paul Summers, Giorgio Marotta, Luca Mainardi, Gianni Pezzoli, Luigi Zecca, Antonella Cost. Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease. Frontiers in aging neuroscience. vol 8. 2016-09-06. PMID:27597825. |
parkinson's disease (pd) is a progressive neurodegenerative disorder in which the major pathologic substrate is a loss of dopaminergic neurons from the substantia nigra. |
2016-09-06 |
2023-08-13 |
human |
| Ioannis U Isaias, Paula Trujillo, Paul Summers, Giorgio Marotta, Luca Mainardi, Gianni Pezzoli, Luigi Zecca, Antonella Cost. Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease. Frontiers in aging neuroscience. vol 8. 2016-09-06. PMID:27597825. |
our main objective was to determine the correspondence between changes in the substantia nigra, evident in neuromelanin and iron sensitive magnetic resonance imaging (mri), and dopaminergic striatal innervation loss in patients with pd. |
2016-09-06 |
2023-08-13 |
human |
| Ioannis U Isaias, Paula Trujillo, Paul Summers, Giorgio Marotta, Luca Mainardi, Gianni Pezzoli, Luigi Zecca, Antonella Cost. Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease. Frontiers in aging neuroscience. vol 8. 2016-09-06. PMID:27597825. |
our results suggest that neuromelanin-mri can be used for quantifying substantia nigra pathology in pd where it closely correlates with dopaminergic striatal innervation loss. |
2016-09-06 |
2023-08-13 |
human |
| Ngoc B Lu-Nguyen, Martin Broadstock, Rafael J Yáñez-Muño. Efficient Expression of Igf-1 from Lentiviral Vectors Protects In Vitro but Does Not Mediate Behavioral Recovery of a Parkinsonian Lesion in Rats. Human gene therapy. vol 26. issue 11. 2016-09-01. PMID:26222254. |
striatal transduction of such vectors into 6-ohda-lesioned rats, however, provided neither protection of dopaminergic substantia nigra neurons nor improvement of animal behavior. |
2016-09-01 |
2023-08-13 |
human |
| Goichi Beck, Koei Shinzawa, Hideki Hayakawa, Kousuke Baba, Hisae Sumi-Akamaru, Yoshihide Tsujimoto, Hideki Mochizuk. Progressive Axonal Degeneration of Nigrostriatal Dopaminergic Neurons in Calcium-Independent Phospholipase A2β Knockout Mice. PloS one. vol 11. issue 4. 2016-09-01. PMID:27078024. |
in ipla2β-ko mice, focal loss of nerve terminals positive for th and dat was found from 56 weeks (early clinical stage), although ipla2β-ko mice at 56 weeks showed no significant decrease in the number of dopaminergic neurons in the substantia nigra compared with age-matched wt mice, as reported previously. |
2016-09-01 |
2023-08-13 |
mouse |
| Kazuhiko Nakadate, Sawako Tanaka-Nakadat. Three-Dimensional Electron Microscopy Reconstruction of Degenerative Dopaminergic Neurons Surrounded by Activated Microglia in Substantia Nigra. Ultrastructural pathology. vol 39. issue 6. 2016-08-31. PMID:26111207. |
three-dimensional electron microscopy reconstruction of degenerative dopaminergic neurons surrounded by activated microglia in substantia nigra. |
2016-08-31 |
2023-08-13 |
human |
| Uma A Mukherjee, Sang-Bing Ong, Sang-Ging Ong, Derek J Hausenlo. Parkinson's disease proteins: Novel mitochondrial targets for cardioprotection. Pharmacology & therapeutics. vol 156. 2016-08-31. PMID:26481155. |
in dopaminergic neurons of the substantia nigra, these pd proteins, which include parkin, pink1, dj-1, lrrk2, and α-synuclein, play essential roles in preventing cell death-through maintaining normal mitochondrial function, protecting against oxidative stress, mediating mitophagy, and preventing apoptosis. |
2016-08-31 |
2023-08-13 |
Not clear |
| Shuke Nie, Yan Xu, Guiqin Chen, Kai Ma, Chao Han, Zhenli Guo, Zhentao Zhang, Keqiang Ye, Xuebing Ca. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents. Neuropharmacology. vol 99. 2016-08-30. PMID:26282118. |
dopaminergic neurons loss in the substantia nigra (sn) and dopamine (da) content loss in the striatum correlate well with disease severity in parkinson's disease (pd). |
2016-08-30 |
2023-08-13 |
mouse |
| Rongyi Zhou, Xinmin Han, Jiaojiao Wang, Jichao Su. Baicalin may have a therapeutic effect in attention deficit hyperactivity disorder. Medical hypotheses. vol 85. issue 6. 2016-08-30. PMID:26604025. |
animal experiments showed that it protects dopaminergic neurons in the striatum, hippocampus and substantia nigra. |
2016-08-30 |
2023-08-13 |
Not clear |
| Guillaume Daniel, Alessandra Musso, Elpida Tsika, Aris Fiser, Liliane Glauser, Olga Pletnikova, Bernard L Schneider, Darren J Moor. α-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9). Neurobiology of disease. vol 73. 2016-08-29. PMID:25461191. |
intriguingly, the delivery of an atpase-deficient form of atp13a2 (d513n) to the substantia nigra is sufficient to induce dopaminergic neuronal degeneration and motor deficits in rats, potentially suggesting a dominant-negative mechanism of action. |
2016-08-29 |
2023-08-13 |
human |
| Pavle Matak, Andrija Matak, Sarah Moustafa, Dipendra K Aryal, Eric J Benner, William Wetsel, Nancy C Andrew. Disrupted iron homeostasis causes dopaminergic neurodegeneration in mice. Proceedings of the National Academy of Sciences of the United States of America. vol 113. issue 13. 2016-08-29. PMID:26929359. |
there was gradual depletion of dopaminergic projections in the striatum followed by death of dopaminergic neurons in the substantia nigra. |
2016-08-29 |
2023-08-13 |
mouse |
| Patricia Tagliaferro, Tatyana Kareva, Tinmarla F Oo, Olga Yarygina, Nikolai Kholodilov, Robert E Burk. An early axonopathy in a hLRRK2(R1441G) transgenic model of Parkinson disease. Neurobiology of disease. vol 82. 2016-08-24. PMID:26192625. |
we have shown that as human bac transgenic hlrrk2(r1441g) mice age, they exhibit two abnormalities in the nigrostriatal dopaminergic system: an axonopathy and a diminished number of dendrites in the substantia nigra (sn). |
2016-08-24 |
2023-08-13 |
mouse |
| Celia van der Merwe, Jonathan Carr, Brigitte Glanzmann, Soraya Bardie. Exonic rearrangements in the known Parkinson's disease-causing genes are a rare cause of the disease in South African patients. Neuroscience letters. vol 619. 2016-08-24. PMID:27001088. |
parkinson's disease (pd) is a neurodegenerative movement disorder characterized by the loss of dopaminergic neurons in the substantia nigra of the midbrain. |
2016-08-24 |
2023-08-13 |
Not clear |
| Fatemeh Nouri Emamzadeh, Harmesh Aojula, Patrick C McHugh, David Allso. Effects of different isoforms of apoE on aggregation of the α-synuclein protein implicated in Parkinson's disease. Neuroscience letters. vol 618. 2016-08-22. PMID:26921451. |
parkinson's disease is a progressive brain disorder due to the degeneration of dopaminergic neurons in the substantia nigra. |
2016-08-22 |
2023-08-13 |
Not clear |